Terumo Corporation · TSE:4543
Terumo — Investor Presentation (November 2020)
13 slides from Terumo's investor presentation, Nov 5, 2020
Slide 1: Alliance Business
Alliance Business Develop a Growth Driver by Infusing Core Technologies with a New Business Model November 5, 2020 Shinjiro Sato President and CEO Terumo Corporation
Slide 2: Safe Harbor for Forward-Looking Statements and Use of Document
Safe Harbor for Forward-Looking Statements and Use of Document Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future even
Slide 3: "Alliance" Business within Terumo
“Alliance” Business within Terumo B2B: Provides pharma w/ devices to add additional A division of General Hospital company value to drug and contract manufacturing with annual sales of 20 BJPY Contract Provide manufacturing device Cardiac & Vascular Alliance 53% 14% Pharmaceutical companies Sales Ge
Slide 4: Alliance Business Trajectory
Alliance Business Trajectory Next Mid- to Long-term Growth Strategy FY16～ High-calorie nutrient solutions Erythropoiesis- containing multivitamins stimulating protein Growth stage Deploy product pipeline, prepare for next stage FY09～ Heparin in saline Biologics, Drug Kit Administration Device Develo
Slide 5: Entering Growth Phase
Entering Growth Phase (100 million yen) 250 Drug Kit Administration Device (primarily outside Japan) 200 150 Prefilled syringes (primarily Japan) 100 Provide prefillable container (PLAJEX) 50 CDMO Fully-integrated manufacturing 0 from molding thru packing FY16 FY17 FY18 FY19 ©TERUMO CORPORATION 5 /1
Slide 6: Unique Business Model
Unique Business Model Traditional Model Terumo’s Model: CDMO + α Three-way collaboration is required Terumo plays a double roles, device company and contract manufacturer Pharmaceutical Pharmaceutical company company Contract Provide devices to add Device manufacturer company additional value to d
Slide 7: Captured Emerging Needs for Change in Drug Trend
Captured Emerging Needs for Change in Drug Trend Change in Drug Trend Small-molecule: Large-molecule and biopharmaceutical: Orally administered drugs Injected drugs Emerging challenges Terumo’s solutions Delicateness of biologics Silicone oil-free, aseptic filling Technologies to handle small
Slide 8: Next Moves for Sustainable Growth
Next Moves for Sustainable Growth Use core technologies to further strengthen customization capability for increasingly diverse drugs New needs Core technologies High viscosity High volume New Drug Patch self-injection Delivery Intradermal Intradermal administration, etc Tapered needles Patc
Slide 9: Seamlessly Expanding Development Pipeline
Seamlessly Expanding Development Pipeline Deals projected from ongoing co-developments Erythropoiesis-stimulating protein Adalimumab biosimilar Teriparatide acetate +10 deals 9 more drugs 12 deals ～FY19 FY20～FY26 ©TERUMO CORPORATION 9 /12
Slide 10: Expand Production Capability thru Constant Investments
Expand Production Capability thru Constant Investments (100 million JPY) CAPEX investment for production 250 200 150 100 50 0 FY01～FY05 FY06～FY10 FY11～FY15 FY16～FY20 ©TERUMO CORPORATION 10 /12
Slide 11: KSF to Secure Sustainable Growth Trajectory
KSF to Secure Sustainable Growth Trajectory Ample drug delivery technologies to meet a wide variety of drugs Filling and sterilization technologies to manage sensitive drugs Knowledge and experience of development, evaluation, regulatory affairs, and clinical development for combination products Tra
Slide 12: Extend Our Market Reach with "Alliance" Model
Extend Our Market Reach with “Alliance” Model Capture the expansion of healthcare scene by innovation of combined technologies A diversity of core technologies Traditional A Hospitals, model of Commercialization Clinics B medtech C company D ・ ・ Home and Pharmaceutical ＋ community care facilities co
Slide 13: <“TERUMO
<“TERUMO